This technology proposes to modulate mitofusin-regulated microtubule acetylation for the treatment of peripheral neuropathy.
Mutations in Mitofusin-2 (MFN2) cause sensory loss in peripheral neuropathies like Charcot-Marie-Tooth Type 2A (CMT2A), with potential ties to a loss of acetylated tubulin. Mitochondria contacts with microtubules are hotspots of α-tubulin acetylation through the recruitment of α-tubulin acetyltransferase (ATAT1) by MFN2, and mutations of MFN2 that impact this activity cause CMT2A. While histone deacetylase (HDAC) inhibition has been identified as a promising therapeutic strategy for peripheral neuropathies, there are concerns about tubulin specificity. This suggests that targeting αTAT1 activity may offer a successful and tubulin-specific therapeutic approach for restoring sensory neuron function in CMT2A and potentially other related CMT subtypes.
This technology describes methods for the modulation of acetyltransferase 1 (ATAT1) activity for the prevention of peripheral axonal degeneration caused by a disruption to acetylated tubulin-mediated mitochondrial transport. This technology proposes to target MFN2-mediated recruitment of ATAT1 to mitochondrial membranes to restore tubulin acetylation and mitochondrial transport using tubulin deacetylase inhibitors or tubulin acetylation activators. The identification of the importance of acetylation also enables risk assessment for patients with developing peripheral neuropathies. Modulation of mitochondrial transport through MFN2-dependent recruitment of ATAT1 potentially represents a therapeutic approach for CMT2A and other peripheral neuropathies.
This technology has been validated using primary sensory neurons isolated from mice and Drosophila.
Patent Pending(US19/547,316)
IR CU24079
Licensing Contact: Kristin Neuman